Clinical characteristics, treatment options, and prognosis of myeloid sarcoma: analysis using the SEER database

BACKGROUNDMyeloid sarcoma (MS) is a very rare hematologic disorder. This study analyzes the early treatment options for patients with different types of MS and explores the prognostic factors of MS. METHODSPatients aged 15 years and older with MS in the SEER database (diagnosed from 2000 to 2018) we...

Full description

Saved in:
Bibliographic Details
Published in:Hematology (Luxembourg) 2023-12, Vol.28 (1), p.2247898-2247898
Main Authors: Liang, Jingjing, Yang, Liu, Yang, Bo, Tian, Yaru, Ren, Juan, Yang, Linhua
Format: Article
Language:English
Subjects:
myeloid sarcoma
overall survival
prognostic factors
SEER
treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUNDMyeloid sarcoma (MS) is a very rare hematologic disorder. This study analyzes the early treatment options for patients with different types of MS and explores the prognostic factors of MS. METHODSPatients aged 15 years and older with MS in the SEER database (diagnosed from 2000 to 2018) were selected, excluding those with an unknown first course of treatment, an unknown location of disease, and less than 1 month of follow-up. Statistical methods used a chi-square test to compare clinical characteristics; Kaplan-Meier analysis to compare survival differences; and Cox proportional risk models to identify prognostic factors affecting overall survival (OS). RESULTSData were collected from 472 patients: 244 patients with isolated myeloid sarcoma (IMS) and 228 patients with non-isolated myeloid sarcoma (non-IMS). IMS patients mostly chose local treatment, while non-IMS patients mostly chose chemotherapy. There was a significant difference in OS between IMS patients treated with combined treatment and those without treatment. For non-IMS, treated patients had longer OS than untreated, but the difference was not statistically significant. Among adult patients, those younger than 60 years had a better prognosis. Patients with the urinary system, digestive system, reproductive system and chest and abdomen as the initial site had a better prognosis. CONCLUSIONSEarly combination therapy in IMS patients had a longer OS, and chemotherapy combined with radiotherapy/surgery should be the treatment of choice. For non-IMS patients, early combination therapy did not show a significant advantage. Age and location of first presentation were independent factors affecting MS patients' long-term prognosis.
ISSN:1607-8454
1607-8454
DOI:10.1080/16078454.2023.2247898